Leukemia Clinical Trials in Pittsburgh

Showing 521-540 of 1,534 trials

A Study to Investigate LYL845 in Adults With Solid Tumors

NCT05573035

This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).

MelanomaNon-small Cell Lung CancerColorectal Cancer

Lyell Immunopharma, Inc.39 participantsStarted Dec 2022

Sacramento, California, United States • Santa Monica, California, United States • Stanford, California, United States +15 more locations

Active Not RecruitingPhase 3< 1 mile

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

Epithelial Ovarian CancerPrimary PeritonealFallopian Tube Cancer+4 more

pharmaand GmbH1,097 participantsStarted May 2018

Phoenix, Arizona, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +235 more locations

A Study to Investigate LYL845 in Adults With Solid Tumors

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Leukemia Trials in Other Cities

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Registry of Arthrex Hand and Wrist Products

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Infant Formula in Infants and Children With Cow's Milk Allergy

ALL Adult Consortium Trial: Adult ALL Trial

MAGIC Ruxolitinib for aGVHD

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Medical Access Program for Patritumab Deruxtecan

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

AVID100 in Advanced Epithelial Carcinomas

A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Other Conditions in Pittsburgh